Literature DB >> 10541218

Non-transplant uses of mycophenolate mofetil.

D Jayne1.   

Abstract

The immunosuppressive drug mycophenolate mofetil is a potential new treatment for autoimmune renal disease. In addition to its effects in modulating the autoimmune response, mycophenolate mofetil reduces adhesion molecule expression and delays the progression of renal failure. Data from experimental models of glomerulonephritis, especially of lupus nephritis, have demonstrated that mycophenolate mofetil reverses both inflammatory and autoimmune aspects of disease and influences outcome. As yet, clinical experience with mycophenolate mofetil remains anecdotal but provides a strong platform for the scientific evaluation of mycophenolate mofetil as a new therapeutic agent for these conditions in the future.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10541218     DOI: 10.1097/00041552-199909000-00005

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  5 in total

1.  Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria.

Authors:  Eduardo F Borba; Lissiane K Guedes; Romy B Christmann; Camille P Figueiredo; Célio R Gonçalves; Eloisa Bonfá
Journal:  Rheumatol Int       Date:  2006-05-31       Impact factor: 2.631

2.  Inosine monophosphate dehydrogenase (IMPDH) inhibition in vitro suppresses lymphocyte proliferation and the production of immunoglobulins, autoantibodies and cytokines in splenocytes from MRLlpr/lpr mice.

Authors:  C A Jonsson; H Carlsten
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

Review 3.  Cytomegalovirus infection and abdominal pain with mycophenolate mofetil: is there a link?

Authors:  H Gallagher; P A Andrews
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

4.  Successful treatment of refractory thrombocytopenia with mycophenolate mofetil in a patient with systemic lupus erythematosus.

Authors:  Hyun Kyu Chang
Journal:  J Korean Med Sci       Date:  2005-10       Impact factor: 2.153

5.  Mycophenolic Acid Synergizing with Lipopolysaccharide to Induce Interleukin-1β Release via Activation of Caspase-1.

Authors:  Xue-Chan Huang; Yi He; Jian Zhuang; Juan He; Gui-Hu Luo; Jiao-Chan Han; Er-Wei Sun
Journal:  Chin Med J (Engl)       Date:  2018-07-05       Impact factor: 2.628

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.